Rimantadine-Darnitsa (rimantadine hydrochloride) tablets 0.05 g. №20

Description

Rimantadine-Darnitsa (rimantadine hydrochloride) tablets 0.05 g. №20

Composition 

active ingredient: rimantadine;

1 tablet contains rimantadine hydrochloride 50 mg;

excipients: lactose monohydrate, corn starch, povidone, anhydrous colloidal silicon dioxide, magnesium stearate.

Dosage form

Tablets.

Basic physical and chemical properties: tablets of white or white color with a yellowish tint, flat-cylindrical shape, with a chamfer and risk.

Pharmacological group

Antiviral agents for systemic use. Cyclic amines.
ATX code J05A C02.

Pharmacological properties

Rimantadine hydrochloride – a derivative of amantadine, has a pronounced antiviral activity. It is effective against various type A influenza viruses, and also has an antitoxic effect in influenza caused by type B virus. Rimantadine inhibits viral replication in the early stages of the cycle by disrupting the formation of the viral envelope. Genetic studies have shown that the specific protein of the M2 gene of the virion is of great importance in the antiviral effect of rimantadine against the influenza A virus. In vitro, rimantadine inhibits the replication of all three antigenic subtypes (H1N1, H2N2, H3N3) of the influenza virus identified in humans. Rimantadine does not affect the immunogenic properties of the inactivated influenza A vaccine.

Rimantadine-Darnitsa is also effective against arboviruses, which are the causative agents of tick-borne encephalitis.

Indications

It is intended for treatment in the early stages of infectious diseases caused by influenza A viruses in adults and children over 7 years old.
It is also effective as a prophylactic agent for preventing influenza type A disease in patients of the above age group.

Contraindications

The drug Rimantadine-Darnitsa in question is contraindicated for use in cases where the patient has severe hypersensitivity (allergy) to the main or one of the auxiliary components.
It is contraindicated to use at:

• severe violations of the kidneys, liver;
• thyrotoxicosis.

Simultaneous use with alcohol is contraindicated (dangerous reactions from the nervous system are possible).
Simultaneous use with paracetamol and acetylsalicylic acid reduces the effectiveness of rimantadine.
In turn, it was noted that rimantadine reduces the effectiveness of antiepileptic drugs.
This drug is prescribed with caution to patients with diseases of the gastrointestinal tract, severe diseases of the heart and heart rate, and to the elderly. In these cases, it is recommended to reduce the dose of the drug.
Not used in pediatrics until the age of 7.

Application during pregnancy and lactation

This drug is contraindicated in pregnant women, as well as when planning pregnancy.
If it is necessary to take the drug during breastfeeding, lactation is suspended.

Method of administration and dosage

The drug Rimantadine-Darnitsa is taken orally after meals with water.
The use of rimantadin should be started as early as possible, immediately after the first symptoms of influenza appear, preferably in the first 48 hours after the onset of the first symptoms of influenza (aching muscles and bones, high temperature – above 38.5 ° C, fever alternating with chills, in the absence of reactions in the form of a runny nose or cough in the first 3 days).
Recommended dosages:

• for the treatment of adults, for 5 days, day 1 – 100 mg 3 times a day, 2-3 days – 100 mg 2 times a day, on the 4-5th day – 100 mg 1 time in a day;
• for the treatment of children from 11 to 14 years old – 50 mg 3 times a day;
• for the treatment of children from 7 to 10 years old – 50 mg 2 times a day.
• for the treatment of patients over 65 years old – 100 mg 2 times a day.
• for the prevention of influenza – within 10-15 days after the beginning of the influenza epidemic, 50 mg (1 tablet) 1 time per day.

The faster you start using the drug at the first signs of illness, the better the result will be.
Increasing the dosage will not improve the therapeutic effect, however, it can cause unwanted side effects, therefore, the recommended dosage should not be exceeded.

Overdose

With excessive use, you may experience:

• agitation, hallucinations;
• heart rhythm disturbances, arrhythmia, hypesthesia;
• fever, chills, sweating, tearing;
• dysphagia, constipation, increased urination;
• stomatitis, pain in the eyes.
• Treatment:
• stop taking the drug;
• perform gastric lavage;
• take enterosorbents;
• children – physostigmine.

Hemodialysis is not effective.

Side effects

The drug Rimantadine-Darnitsa is usually well tolerated when used in the recommended doses.

The most common side effects were:

• dyspepsia in the form of nausea, vomiting, less often – abdominal pain, diarrhea, indigestion, dry mouth, anorexia;
• insomnia, dizziness, headache, increased fatigue, convulsions, confusion, ataxia;
• heart failure, edema, cardiac conduction disturbances (blockade), tachycardia;
• arterial hypertension, cerebrovascular disorders, fainting;
• galactorrhea;
• cough, shortness of breath, bronchospasm;
• asthenia, exacerbation of chronic diseases.

Usually disappear after drug withdrawal.